NAUT News and Press, Nautilus Biotechnology Inc. From 10/15/21

The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....

SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of ...

Growth and value equities have taken a hit in September, which is historically a terrible month for stocks, the politics of a shutdown and potential default look to be temporary headwinds. I am feeling very good at the moment regarding my positions and exposure to durable trends in th...

SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the ...

Nautilus Biotechnology seeks to deliver on the untapped potential of the human proteome. The company debuted for public trade on Nasdaq Global Select Market on 6/10/2021. The company started off with gross proceeds of $345 million from the business combination with a SPAC. F...

Nautilus Biotechnology, Inc. (NAUT) Q2 2021 Earnings Conference Call August 10, 2021 8:00 AM ET Company Participants Sujal Patel – Co-Founder and Chief Executive Officer Parag Mallick – Co-Founder and Chief Scientist Anna Mowry – Chief Financial Officer Conference Call Pa...

SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome, today reported financial results for the second quarter e...

SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karl Voss, Ph.D., as Vice President of Life ...

Gainers: JD +4.7%. MVST +3.9%. MDRX +3.7%. MCFE +2.8%. ADVM +2.8%. Losers: ETON -12.9%. GDS -6.7%. PRTK -5.1%. PDD -3.0%. NAUT -1.7%. For further details see: MVST, MDRX, ETON and GDS among after hours movers

Shares of Nautilus Biotechnology (NAUT +50.6%) are surging in afternoon trading following a CNBC report that Amazon (AMZN +0.6%) held a ~$15M stake in the company at the end of Q2. The disclosure of the $14.7M investment was made in a recent Amazon SEC Form 13F filing. Nautilus just went publ...